In the present study, we investigated the impact of the treatment with ruxolitinib on cytoskeleton-related genes expression and we identified aurora kinase A (AURKA) and B (AURKB) as promising targets for pharmacological intervention in MPN cellular models. Here, AURKA is linked to myeloproliferative neoplasm.